öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£º¼ÖÀò
ÐÔ±ð£º
ÈËÆøÖ¸Êý£º281

ËùÊôԺУ£º´óÁ¬Ò½¿Æ´óѧ
ËùÊôԺϵ£º¼ìÑéҽѧԺ
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£º²©µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÁÙ´²¼ìÑéÕï¶Ïѧ
Ñо¿ÁìÓò£º Ö×Áöϸ°û±íÃæÌÇÁ´ÐÞÊÎÆ׵Ľ¨Á¢£»Ö×Áöϸ°ûÌÇÁ´ºÏ³Éµ÷¿ØµÄÑо¿£»»ùÓÚlncRNA¡¢miRNAΪ̽... [Õ¹¿ª]


Ñо¿ÁìÓò£º Ö×Áöϸ°û±íÃæÌÇÁ´ÐÞÊÎÆ׵Ľ¨Á¢£»Ö×Áöϸ°ûÌÇÁ´ºÏ³Éµ÷¿ØµÄÑо¿£»»ùÓÚlncRNA¡¢miRNAΪ̽Õëµ÷¿ØÌÇÁ´ÔÚÖ×Áö·¢Éú¡¢·¢Õ¹¼°ÄÍÒ©ÖеŦÄÜ»úÖÆÑо¿£»Ö×Áö·¢Éú¡¢·¢Õ¹¼°ÄÍÒ©Ïà¹ØÌÇÀàÎïÖʱêÖ¾ÎïµÄɸѡ¼°¼ø¶¨ [ÊÕÆð]




¸öÈ˼òÊö :
¼ÖÀò£¬Ò½Ñ§²©Ê¿£¬½ÌÊÚ£¬²©Ê¿Éúµ¼Ê¦¡£2009ÄêÈÙ»ñÁÉÄþÊ¡¡°°ÙǧÍòÈ˲Ź¤³Ì¡±°ÙÈ˲ã´ÎÓÅÐãÈ˲ţ»2013Äê»ñ´óÁ¬Ò½¿Æ´óѧ¡°Ó¢²Å¹¤³Ì¡±ÓÅÐãÈ˲ÅÖ§³Ö¼Æ»®£»ÈÙ»ñ2015Äê¶È´óÁ¬Ò½¿Æ´óѧÓÅÐã¿Æ¼¼¹¤×÷Õß¡£ÏÖÈÎÖ°ÓÚ´óÁ¬Ò½¿Æ´óѧ¼ìÑéҽѧԺ¡£2010Äê»ñµÃ¸ßУÈÕÔª´û¿î¼Æ»®×ÊÖú¸°ÈÕ±¾²úÒµ¼¼Êõ×ÛºÏÑо¿ËùÌÇ¿ÆѧÑо¿ÖÐÐÄ´ÓʹØÓÚÌÇÁ´ÓëÖ×ÁöÄÍÒ©ÐÔÖ®¼ä¹ØϵµÄÑо¿£¬·ÃÎÊѧÕß¡£½üÄêÀ´Ö÷³Ö¹ú¼Ò×ÔÈ»»ù½ð¡¢ÁÉÄþÊ¡×ÔÈ»»ù½ð¡¢ÁÉÄþÊ¡½ÌÓýÌü´´ÐÂÍŶÓÏîÄ¿¡¢ÁÉÄþÊ¡½ÌÓýÌü¹¥¹Ø¿ÎÌâ¡¢ÁÉÄþÊ¡¸ß²ã´ÎÈ˲Å×ÊÖúÏîÄ¿£¨ÁÉÄþÊ¡°ÙǧÍòÈ˲Ź¤³Ì×ÊÖúÏîÄ¿£©µÈÏîÄ¿£»2012Äê×÷ΪÖ÷ҪѧÊõ¹Ç¸É²Î¼Ó¹ú¼ÒÖØÒª»ù´¡Ñо¿·¢Õ¹¼Æ»®ÏîÄ¿£¨973¼Æ»®£©Ò»Ïî¡£2013¡¢2014¡¢2016Äָ꣬µ¼µÄ±¾¿ÆÉú·Ö±ð»ñµÃ¡°´óѧÉú¿Æ¼¼ÂÛÎÄ´óÈü¡± ¹ú¼Ò¼¶ÈýµÈ½±¡¢Ê¡¼¶ÌصȽ±£»Ö¸µ¼µÄ2Ãû˶ʿÑо¿Éú»ñµÃ¡°ÁÉÄþÊ¡ÓÅÐã˶ʿѧλÂÛÎÄ¡±¡£ µ½Ä¿Ç°ÎªÖ¹£¬ÒÑÔÚ°üÀ¨Oncogene, Molecular & Cellular Proteomics, Cell Death & DiseaseµÈSCIÊÕ¼µÄ¸ßˮƽ¹ú¼ÊÔÓÖ¾ÉÏ·¢±íÈýÊ®ÓàƪѧÊõÂÛÎÄ¡£¸±Ö÷±à¼°²Î±à½Ì²Ä¡¢×¨ÖøµÈ10²¿¡£

¿ÆÑй¤×÷ :
ÔÚÑÐÏîÄ¿
1. ¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿£¬**£¬°×Ѫ²¡ÄÍÒ©ÌǸ´ºÏÎï±êÖ¾ÎïµÄɸѡ¡¢¼ø¶¨¼°Æ书ÄÜÑо¿£¬2015/01-2018/12£¬72Íò£¬ÔÚÑУ¬ÏîÄ¿¸ºÔðÈË
2. ºáÏò¿ÎÌ⣨´óÁ¬½ð¸«ÉúÎï¿Æ¼¼·¢Õ¹ÓÐÏÞ¹«Ë¾£©£¬¼¦ÅßÓªÑø×éºÏÎïÑÓ»ºË¥ÀϵÄʵÑéÑо¿£¬2016/06-2018/05£¬50Íò£¬ÔÚÑУ¬ÏîÄ¿¸ºÔðÈË
3. ¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿£¬**£¬ÌÇ»ùÒòÔÚ°×Ѫ²¡ÄÍÒ©ÐÔÖеÄÌØÕ÷ÐԸı估ÆäÕï¶Ï¼ÛÖµ£¬2013/01-2016/12£¬70Íò£¬ÒѽáÌ⣬ÏîÄ¿¸ºÔðÈË
4. ÁÉÄþÊ¡×ÔÈ»»ù½ðÏîÄ¿£¬**£¬ÌÇÁ´ÔÚ°×Ѫ²¡ÄÍÒ©ÐÔÖеı仯¹æÂɼ°Æ书ÄÜ»úÖÆÑо¿£¬2014/07-2016/06£¬5Íò£¬ÒѽáÌ⣬ÏîÄ¿¸ºÔðÈË
5. ¹ú¼ÒÖØÒª»ù´¡Ñо¿·¢Õ¹¼Æ»®ÏîÄ¿£¨973¼Æ»®£©£¬2012CB822103£¬Ö×ÁöµÄÌÇ»¯Ñ§ÉúÎïѧǰÑØÑо¿©¤£¨·Ö¿ÎÌ⣩ÌÇÁ´¶ÔÖ×Áöϸ°ûÉúÎïѧÐÐΪµÄÓ°Ïì¼°»úÖÆÑо¿£¬2012/01-2016/12£¬540Íò£¬ÒѽáÌ⣬²ÎÓëÈË
6. ºáÏò¿ÎÌ⣨´óÁ¬½ð¸«ÉúÎï¿Æ¼¼·¢Õ¹ÓÐÏÞ¹«Ë¾£©£¬ÓªÑø×éºÏÎï¶Ô»úÌå¸Éϸ°ûºÍ»ùÒòËðÉË×ÔÖ÷ÐÞ¸´×÷ÓõÄʵÑéÑо¿£¬2015/07-2016/06£¬60Íò£¬ÒѽáÌ⣬ÏîÄ¿¸ºÔðÈË
7. ´óÁ¬Ò½¿Æ´óѧÊ×½ìÓ¢²ÅÖ§³ö¼Æ»®£¬2013/06-2016/06£¬40Íò£¬ÒѽáÌ⣬ÏîÄ¿¸ºÔðÈË
8. ÁÉÄþÊ¡¸ß²ã´ÎÈ˲Å×ÊÖúÏîÄ¿£¨ÁÉÄþÊ¡°ÙǧÍòÈ˲Ź¤³Ì×ÊÖúÏîÄ¿£©£¬**£¬ÌÇ»ùÒòÔÚ°×Ѫ²¡ÄÍÒ©ÖеÄÌØÕ÷ÐԸı估ÆäÕï¶Ï¼ÛÖµ£¬2013/01-2015/12£¬2Íò£¬ÒѽáÌ⣬ÏîÄ¿¸ºÔðÈË
´ú±íÐÔÎÄÕ£¨* ͨѶ×÷Õߣ©
1. Cai H, Zhou H, Miao Y, Li N, Zhao L, Jia L*, MiRNA expression profiles reveal the involvement of miR-26a, miR-548l and miR-34a in hepatocellular carcinoma progression through regulation of ST3GAL5, Lab Invest, 2017 Feb 20, doi: 10.1038/labinvest.2017.12. (IF=4.202)
2. Miao Y, Zheng W, Li N, Su Z, Zhao L, Zhou H, Jia L*, MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway, Sci Rep, 2017, 7:41942. (IF=5.228)
3. Ma X, Dong W, Su Z, Zhao L, Miao Y, Li N, Zhou H, Jia L*, Functional roles of sialylation in breast cancerprogression through miR-26a/26b targeting ST8SIA4, Cell Death Dis, 2016, 7(12): e2561. (IF=5.378)
4. Cheng L, Gao S, Song X, Dong W, Zhou H, Zhao L, Jia L*, Comprehensive N-glycan profiles of hepatocellular carcinoma reveal association of fucosylation with tumor progression and regulation of FUT8 by microRNAs, Oncotarget, 2016, 7(38): 61199-61214. (IF=5.008)
5. Zhao L, Li Y, Song X, Zhou H, Li N, Miao Y, Jia L*, Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia, Oncotarget, 2016, 7(37): 60074-60086. (IF=5.008)
6. Li Y, Luo S, Dong W, Song X, Zhou H, Zhao L, Jia L*, Alpha-2, 3-sialyltransferases regulate the multidrug resistance of chronic myeloid leukemia through miR-4701-5p targeting ST3GAL1, Laboratory Investigation, 2016, 96(7): 731-740. (IF=4.202)
7. Li N, Liu Y, Miao Y, Zhao L, Zhou H, Jia L*, MicroRNA-106b targets FUT6 to promote cell migration, invasion, and proliferation in human breast cancer, Iubmb Life, 2016, 68(9): 764-775. (IF=2.653)
8. Zhou H, Li Y, Song X, Zhao Y, Cheng L, Zhao L, Jia L*, CHST11/13 Regulate the Metastasis and Chemosensitivity of Human Hepatocellular Carcinoma Cells Via Mitogen-Activated Protein Kinase Pathway, Digestive Diseases and Sciences, 2016, 61(7): 1972-1985. (IF=2.516)
9. Zhao L, Feng X, Song X, Zhou H, Zhao Y, Cheng L, Jia L*, miR-493-5p attenuates the invasiveness and tumorigenicity in human breast cancer by targeting FUT4, Oncology Reports, 2016, 36(2): 1007-1015. (IF=2.486)
10. Feng X, Zhao L, Gao S, Song X, Dong W, Zhao Y, Zhou H, Cheng L, Miao X, Jia L*, Increased fucosylation has a pivotal role in multidrug resistance of breast cancer cells through miR-224-3p targeting FUT4, Gene, 2016, 578(2): 232-241. (IF=2.319)
11. Ma H, Zhou H, Song X, Shi S, Zhang J, Jia L*, Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia, Oncogene, 2015, 34(6): 726-7401. (IF= 8.559).
12. Zhang X, Dong W, Zhou H, Li H, Wang N, Miao X, Jia L*, alpha-2,8-Sialyltransferase Is Involved in the Development of Multidrug Resistance via PI3K/Akt Pathway in Human Chronic Myeloid Leukemia, Iubmb Life, 2015, 67(2): 77-87. (IF=2.653)
13. Zhao Y, Li Y, Ma H, Dong W, Zhou H, Song X, Zhang J, Jia L*, Modification of sialylation mediates the invasive properties and chemosensitivity of human hepatocellular carcinoma, Mol Cell Proteomics, 2014, 13(2): 520-536. (IF=7.251)
14. Ma H, Cheng L, Hao K, Li Y, Song X, Zhou H, Jia L*, Reversal effect of ST6GAL 1 on multidrug resistance in human leukemia by regulating the PI3K/Akt pathway and the expression of P-gp and MRP1, PLos One, 2014, 9(1): e85113. (IF=3.057)